Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Sorafenib in unresectable and/or metastatic renal cell carcinoma not eligible or intolerant to immunotherapy
2005-005064-80Phase 2Active
- Sponsor
- DR. JOAQUIM BELLMUNT MOLINS
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sorafenib in renal cell carcinoma (RCC), sponsored by DR. JOAQUIM BELLMUNT MOLINS. Primary endpoint: Median progression-free survival. Started Dec 2005; status: active.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-005064-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005064-80.